mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
0.01 |
mRNA |
TG-100-115 |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.01 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
Vorinostat |
CTRPv2 |
pan-cancer |
AAC |
0.086 |
0.02 |
mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.02 |
mRNA |
BRD-K27986637 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.02 |
mRNA |
Merck60 |
CTRPv2 |
pan-cancer |
AAC |
0.078 |
0.02 |
mRNA |
tacrolimus |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.02 |
mRNA |
SR-II-138A |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.02 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.02 |